Ubs Group Ag Zymeworks Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$6.0 - $16.98 $21,426 - $60,635
-3,571 Reduced 99.3%
25 $0
Q4 2021

Feb 14, 2022
BUY
$15.19 - $29.33 $49,306 - $95,205
3,246 Added 927.43%
3,596 $59,000
Q3 2021

Nov 15, 2021
SELL
$27.35 - $37.28 $11,760 - $16,030
-430 Reduced 55.13%
350 $10,000
Q2 2021

Aug 13, 2021
SELL
$26.5 - $38.23 $220,692 - $318,379
-8,328 Reduced 91.44%
780 $28,000
Q1 2021

May 12, 2021
BUY
$29.83 - $56.81 $44,536 - $84,817
1,493 Added 19.61%
9,108 $287,000
Q4 2020

Feb 11, 2021
BUY
$39.12 - $54.99 $62,748 - $88,203
1,604 Added 26.68%
7,615 $359,000
Q3 2020

Nov 12, 2020
BUY
$29.21 - $46.58 $37,680 - $60,088
1,290 Added 27.32%
6,011 $280,000
Q2 2020

Jul 31, 2020
SELL
$33.67 - $40.0 $90,235 - $107,200
-2,680 Reduced 36.21%
4,721 $170,000
Q1 2020

May 01, 2020
SELL
$24.28 - $49.8 $549,650 - $1.13 Million
-22,638 Reduced 75.36%
7,401 $263,000
Q4 2019

Feb 14, 2020
SELL
$24.84 - $45.46 $306,227 - $560,430
-12,328 Reduced 29.1%
30,039 $1.37 Million
Q3 2019

Nov 14, 2019
BUY
$22.78 - $29.08 $922,043 - $1.18 Million
40,476 Added 2140.45%
42,367 $1.05 Million
Q2 2019

Aug 14, 2019
BUY
$15.0 - $22.49 $11,520 - $17,272
768 Added 68.39%
1,891 $42,000
Q1 2019

May 14, 2019
BUY
$14.02 - $16.74 $15,744 - $18,799
1,123 New
1,123 $18,000
Q4 2018

Feb 14, 2019
SELL
$10.95 - $15.44 $26,126 - $36,839
-2,386 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$12.21 - $16.61 $29,133 - $39,631
2,386 New
2,386 $37,000
Q2 2018

Aug 14, 2018
SELL
$11.13 - $21.86 $4,897 - $9,618
-440 Closed
0 $0
Q1 2018

May 15, 2018
SELL
$7.93 - $13.41 $2,949 - $4,988
-372 Reduced 45.81%
440 $5,000
Q4 2017

Feb 14, 2018
BUY
$6.87 - $9.19 $5,578 - $7,462
812
812 $6,000

Others Institutions Holding ZYME

# of Institutions
1
Shares Held
296K
Call Options Held
0
Put Options Held
0
View Full List

About Zymeworks Inc.

ZYME Quotes by TradingView
  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $872M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email